Literature DB >> 2744073

The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.

P A Philip1, C A James, H J Rogers.   

Abstract

We have studied the effect of cimetidine (800 mg.day-1) administration for three days on debrisoquine 4-hydroxylation in nine healthy extensive metabolizers. The debrisoquine metabolic ratio was significantly increased (p less than 0.01), but the new ratios remained in the extensive metabolizer range (less than 12.6). These data suggest that pre-treatment with cimetidine in usual therapeutic doses will impair debrisoquine 4-hydroxylation, but not enough to alter the apparent oxidation phenotype.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744073     DOI: 10.1007/bf00558167

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Authors:  L Bertilsson; A Aberg-Wistedt
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

Review 2.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

3.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

4.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

5.  Cimetidine-induced alterations in desipramine plasma concentrations.

Authors:  J D Amsterdam; D J Brunswick; L Potter; M J Kaplan
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Reduction of metformin renal tubular secretion by cimetidine in man.

Authors:  A Somogyi; C Stockley; J Keal; P Rolan; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

7.  Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.

Authors:  C von Bahr; C Birgersson; E T Morgan; O Eriksson; M Göransson; E Spina; K Woodhouse
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

Review 8.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

9.  Cimetidine interaction with imipramine and nortriptyline.

Authors:  S A Henauer; L E Hollister
Journal:  Clin Pharmacol Ther       Date:  1984-02       Impact factor: 6.875

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more
  3 in total

1.  Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.

Authors:  N Brynne; Y Böttiger; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

2.  Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.

Authors:  L F Gram; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

3.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.